Gilead Sciences Receives Subpoena from U.S. Department of Health & Human Services Regarding Ranexa®
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD - News) announced today that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa® (ranolazine). Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.